{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/bridging-translation-gap-immuno-oncology#webpage",
"url": "https://www.fortrea.com/insights/bridging-translation-gap-immuno-oncology",
"name": "Bridging the translation gap in immuno-oncology",
"description": "This Fortrea white paper explores challenges associated with immuno-oncology research and the growing need to improve clinical translation across oncology development programs. The content focuses on translational oncology research, clinical translation challenges, tumor microenvironment complexity, preclinical model limitations, and improving clinical relevance within immuno-oncology studies. The white paper highlights difficulties associated with translating preclinical findings into successful clinical outcomes due to variability in immune response, tumor biology complexity, and limitations in existing research models used within oncology research environments. Fortrea discusses scientific considerations and translational approaches designed to improve alignment between preclinical immuno-oncology research and clinical oncology applications. By integrating translational research strategies with clinically relevant oncology research approaches, the white paper provides insights into addressing the translation gap affecting immuno-oncology research and clinical translation efforts."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Bridging the translation gap in immuno-oncology",
"item": "https://www.fortrea.com/insights/bridging-translation-gap-immuno-oncology"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/bridging-translation-gap-immuno-oncology#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/bridging-translation-gap-immuno-oncology#webpage"
},
"headline": "Bridging the Translation Gap in Immuno-Oncology Research and Clinical Translation | Fortrea White Paper",
"description": "This Fortrea white paper explores challenges associated with immuno-oncology research and the growing need to improve clinical translation across oncology development programs. The content focuses on translational oncology research, clinical translation challenges, tumor microenvironment complexity, preclinical model limitations, and improving clinical relevance within immuno-oncology studies. The white paper highlights difficulties associated with translating preclinical findings into successful clinical outcomes due to variability in immune response, tumor biology complexity, and limitations in existing research models used within oncology research environments. Fortrea discusses scientific considerations and translational approaches designed to improve alignment between preclinical immuno-oncology research and clinical oncology applications. By integrating translational research strategies with clinically relevant oncology research approaches, the white paper provides insights into addressing the translation gap affecting immuno-oncology research and clinical translation efforts.",
"genre": "White Paper",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-21",
"dateModified": "2025-03-21",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/bridging-the-translation-gap-in-immuno-oncology.pdf",
"encodingFormat": "application/pdf"
}
}
]
}